BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:35 PM
Aug 06, 2009
 |  BC Extra  |  Top Story

Vectibix meets mCRC endpoint

Amgen Inc. (NASDAQ:AMGN) said Vectibix panitumumab plus FOLFOX4 chemotherapy met the primary endpoint of significantly prolonged progression-free survival in patients with wild-type K-Ras (KRAS) vs. FOLFOX4 alone in the...

Read the full 140 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >